First, we found that 4 successive 2-day apart intravenous injections of T2 combo at a fixed dose (TPEN 5 mg/kg: TPGS 100 mg/kg) showed a statistically significant reduction of Ba/F3 BCR-ABL leukemia cells (– 69%) in leukemia BALB/c mice compared to untreated leukemia group. This evidence concerns the gene BCR and leukemia.